Insight Molecular Diagnostics Inc. Stock Analysis & AI Score
Insight Molecular Diagnostics Inc. (IMDX) has an ST Score of 45.6 (C+), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $9.75 price target (+146.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Insight Molecular Diagnostics Inc. (IMDX) has an ST Score of 45.6 (C+), driven by its Forecast (A) and held back by its Momentum (D). Analysts rate it Buy with a $9.75 price target (+146.8% upside).
- Strongest
- ForecastA
- Weakest
- MomentumD
All factor grades
- ForecastA
- ValuationA-
- Financial StrengthB+
- GrowthC+
- ProfitabilityD
- MomentumD
- Piotroski1/9
Contact
IMDX stock: frequently asked questions
What is IMDX's ST Score?
Insight Molecular Diagnostics Inc. (IMDX) has an ST Score of 45.6 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is IMDX a buy, hold, or sell?
Analysts rate IMDX a Buy, with a price target of $9.75 (+146.8% vs the current price). Our ST Score grades it C+ (45.6/100). The ST Score is a data-driven signal, not a recommendation.
What are IMDX's factor grades?
Valuation A-, Profitability D, Financial Strength B+, Momentum D, Growth C+, Forecast A.
What is IMDX's valuation grade?
Insight Molecular Diagnostics Inc. (IMDX) earns a valuation grade of A-, measured against Medical - Diagnostics & Research peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is IMDX's growth grade?
Insight Molecular Diagnostics Inc. (IMDX) earns a growth grade of C+, measured against Medical - Diagnostics & Research peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is IMDX's profitability grade?
Insight Molecular Diagnostics Inc. (IMDX) earns a profitability grade of D, measured against Medical - Diagnostics & Research peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is IMDX's financial strength grade?
Insight Molecular Diagnostics Inc. (IMDX) earns a financial strength grade of B+, measured against Medical - Diagnostics & Research peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for IMDX?
The average analyst price target for Insight Molecular Diagnostics Inc. (IMDX) is $9.75 from 11 analysts, which is +146.8% versus the recent price of $3.95.
What is IMDX's Piotroski score?
Insight Molecular Diagnostics Inc. (IMDX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.